The interview provides insights into pancreatic cancer management in Italy, focusing on patient eligibility for systemic therapy and the clinical integration of biomarkers such as CEA and CA19-9 into staging decisions. It outlines treatment sequencing across resectable, borderline resectable, locally advanced, and metastatic disease, with emphasis on FOLFIRINOX, and gemcitabine-based regimens. The discussion further explores the pipeline, highlighting RAS inhibitors, immunotherapy combinations, and vaccine strategies as potential avenues for future progress.

This interview was conducted on 23 July 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.